Emerging drugs and vaccines for Candidemia

Candidaantigens and immune responses: implications for a vaccine

(2014) Maria Dolores Moragues et al.   Expert Review of Vaccines

The FDA Reboot of Antibiotic Development

(2013) David M. Shlaes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

(2013) H. W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Undressing the Fungal Cell Wall/Cell Membrane - the Antifungal Drug Targets

(2013) Rui Tada et al.   CURRENT PHARMACEUTICAL DESIGN

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Structural insights into the mechanism of translational inhibition by the fungicide sordarin

(2013) Biprashekhar Chakraborty et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Nonspecific Effect of Mycograb on Amphotericin B MIC

(2012) D. L. Richie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast

(2012) Tatsuya Shibata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials

(2012) D. R. Andes et al.   CLINICAL INFECTIOUS DISEASES

Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections

(2012) Joanne Livermore et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacotherapy approaches to antifungal prophylaxis

(2012) Tzi Bun Ng et al.   EXPERT OPINION ON PHARMACOTHERAPY

Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010

(2012) Dawn M. Sievert et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)

(2012) M. A. Pfaller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults

(2012) Clint S. Schmidt et al.   VACCINE

Antifungal Drug Resistance: Mechanisms, Epidemiology, and Consequences for Treatment

(2011) Michael A. Pfaller   AMERICAN JOURNAL OF MEDICINE

Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis

(2011) Katsura Hata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds

(2011) Mamiko Miyazaki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis

(2011) Nao-aki Watanabe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination immunotherapy of MAb B6.1 with fluconazole augments therapeutic effect to disseminated candidiasis

(2011) Jue-Hee Lee et al.   ARCHIVES OF PHARMACAL RESEARCH

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method

(2011) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

New β-glucan inhibitors as antifungal drugs

(2011) Richard F Hector et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Candida albicans adhesin Als3p is dispensable for virulence in the mouse model of disseminated candidiasis

(2011) I. A. Cleary et al.   MICROBIOLOGY-SGM

Active and Passive Immunization with rHyr1p-N Protects Mice against Hematogenously Disseminated Candidiasis

(2011) Guanpingsheng Luo et al.   PLoS One

T-2307 Shows Efficacy in a Murine Model of Candida glabrata Infection despite In Vitro Trailing Growth Phenomena

(2010) E. Yamada et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study*

(2010) Daniel H. Kett et al.   CRITICAL CARE MEDICINE

Epidemiology of Invasive Mycoses in North America

(2010) Michael A. Pfaller et al.   CRITICAL REVIEWS IN MICROBIOLOGY

Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008–2009)

(2010) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Efficacy of combination immunotherapy of IgM MAb B6.1 and amphotericin B against disseminated candidiasis

(2010) Yongmoon Han   INTERNATIONAL IMMUNOPHARMACOLOGY

In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan

(2010) Toshikazu Yamazaki et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Differential Activities of Three Families of Specific β(1,3)Glucan Synthase Inhibitors in Wild-type and Resistant Strains of Fission Yeast

(2010) Ivone M. Martins et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Candida albicansHyr1p Confers Resistance to Neutrophil Killing and Is a Potential Vaccine Target

(2010) Guanpingsheng Luo et al.   JOURNAL OF INFECTIOUS DISEASES

Successful Treatment of Life-threatening Candida Peritonitis in a Child With Abdominal Non-Hodgkin Lymphoma Using Efungumab and Amphotericin B Colloid Dispersion

(2010) Zdenka Krenova et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

An insight into the antifungal pipeline: selected new molecules and beyond

(2010) Luis Ostrosky-Zeichner et al.   NATURE REVIEWS DRUG DISCOVERY

Small-molecule chromatin-modifying agents: therapeutic applications

(2010) Antonello Mai   Epigenomics

Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557

(2009) A. Schmitt-Hoffmann et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect

(2009) P. A. Warn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Burden of early-onset candidemia: Analysis of culture-positive bloodstream infections from a large U.S. database*

(2009) Andrew F. Shorr et al.   CRITICAL CARE MEDICINE

Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Activity of MGCD290, a Hos2 Histone Deacetylase Inhibitor, in Combination with Azole Antifungals against Opportunistic Fungal Pathogens

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Immunological Reactivity of Blood from Healthy Humans to the rAls3p‐N Vaccine Protein

(2009) Beverlie Baquir et al.   JOURNAL OF INFECTIOUS DISEASES

Treatment of a critically ill child with disseminated Candida glabrata with a recombinant human antibody specific for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin, and voriconazole

(2009) Adam Sutherland et al.   Pediatric Critical Care Medicine

Th1-Th17 Cells Mediate Protective Adaptive Immunity against Staphylococcus aureus and Candida albicans Infection in Mice

(2009) Lin Lin et al.   PLoS Pathogens

In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine

(2008) J. Mitsuyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species

(2008) J. Guinea et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice

(2008) L.K. Najvar et al.   CLINICAL MICROBIOLOGY AND INFECTION

Inhibition ofCandida albicansadhesion by recombinant human antibody single-chain variable fragment specific for Als3p

(2008) Sonia S. Laforce-Nesbitt et al.   FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY

Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007

(2008) Alicia I. Hidron et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Efungumab and caspofungin: pre-clinical data supporting synergy

(2008) S. Hodgetts et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei

(2008) J. Majithiya et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility

(2008) G. E. Brzankalski et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibody Titer Threshold Predicts Anti‐Candidal Vaccine Efficacy Even though the Mechanism of Protection Is Induction of Cell‐Mediated Immunity

(2008) Brad Spellberg et al.   JOURNAL OF INFECTIOUS DISEASES

The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America

(2007) B. Spellberg et al.   CLINICAL INFECTIOUS DISEASES